8-K: Scilex Secures $100M Equity Line, Restructures Warrants, and Repurchases Penny Warrants

Scilex Holding Company has entered into a new $100 million equity line of credit, exchanged existing Tranche B warrants for new ones with adjusted terms, and agreed to repurchase 6.5 million low-exercise price warrants from Oramed Pharmaceuticals Inc.

Summary

• Scilex Holding Company entered into a Common Stock Purchase Agreement with Tumim Stone Capital, LLC for an equity line of credit, allowing the company to sell up to $100,000,000 of newly issued common stock at its discretion.
• Shares purchased under the equity line will be priced at 96% of the lowest daily volume-weighted average price (VWAP) over a one-day period or 97% of the lowest daily VWAP over a three-day period.
• The equity line is subject to an Exchange Cap of 1,390,443 shares (19.99% of shares outstanding prior to the agreement), which can be waived if the average sale price equals or exceeds $8.09.
• As a commitment fee for the equity line, Scilex will issue 150,000 shares of common stock to Tumim Stone Capital, LLC upon the effectiveness of the related registration statement.
• Scilex entered into Warrant Exchange Agreements with certain Tranche B Holders (BPY Limited, Nomis Bay Ltd., and 3i LP) to exchange existing warrants exercisable for an aggregate of 107,142 shares (post-reverse stock split) at $36.40 per share for new warrants.
• The new Tranche B warrants will be exercisable for an aggregate of 500,000 shares at an exercise price of $40.00 per share, expiring on October 8, 2029.
• Scilex also entered into an Option Agreement with Oramed Pharmaceuticals Inc. to repurchase 6,500,000 'Penny Warrants' (exercisable at $0.01 per share) for an aggregate purchase price of $27,000,000.
• An option fee of $1,500,000 will be paid to Oramed in two installments: $750,000 by August 8, 2025, and $750,000 by December 16, 2025.
• The repurchase of Oramed's warrants will occur in two tranches: 3,130,000 warrants for $13,000,000 by September 30, 2025, and 3,370,000 warrants for $14,000,000 by December 31, 2025.
• Completion of the Oramed warrant repurchase will extend the maturity date of Scilex's Senior Secured Promissory Note (Tranche A Note) with Oramed to March 31, 2026, and waive any make-whole payment due thereunder.
• Scilex will reimburse Kelley Drye & Warren LLP $50,000 for legal fees related to the warrant exchange agreements and will pay Proskauer Rose LLP an undisclosed amount for Oramed's legal fees, with a hard deadline of September 15, 2025 for remaining fees.

Sentiment

Score: 6

Explanation: The filing indicates proactive capital management and securing future funding, which are positive. However, the significant dilution potential from the equity line and new warrants, coupled with the substantial cash outlay for the Oramed warrant repurchase, presents a mixed financial outlook. The extension of debt maturity is a favorable outcome.

Positives

• Secured access to up to $100,000,000 in capital through an equity line of credit, providing financial flexibility.
• Repurchasing 6,500,000 'Penny Warrants' from Oramed Pharmaceuticals Inc. at a cost of $27,000,000 (plus a $1,500,000 option fee) eliminates a significant source of potential dilution at a very low exercise price ($0.01 per share).
• The Oramed warrant repurchase agreement includes an extension of the Tranche A Note maturity date to March 31, 2026, and a waiver of the make-whole payment, improving debt terms.
• The warrant exchange with Tranche B Holders simplifies the capital structure by replacing existing warrants with new ones, albeit with a higher share count and exercise price.

Negatives

• The equity line of credit and the issuance of new warrants will result in significant dilution for existing shareholders.
• The new Tranche B warrants increase the number of shares underlying these specific warrants from 107,142 to 500,000, representing a substantial increase in potential future dilution.
• The repurchase of Oramed's Penny Warrants, while reducing low-price dilution, comes at a considerable cash cost of $28,500,000 (including the option fee).
• The exercise price for the new Tranche B warrants is $40.00, which is higher than the previous $36.40, potentially making them less attractive for holders to exercise if the stock price does not significantly increase above this new threshold.
• The company is obligated to issue 150,000 shares as a commitment fee for the equity line, adding to immediate dilution without direct cash proceeds.

Risks

• The company may not be able to obtain stockholder approval for issuing shares exceeding the 19.99% Exchange Cap under the equity line of credit or for Oramed's retained warrants, limiting the full utilization of these agreements.
• The pricing mechanism for the equity line of credit is based on VWAP, exposing the company to market price fluctuations and potential sales at lower prices, leading to greater dilution.
• Failure to make required payments for the Oramed warrant repurchase could result in Oramed retaining the Penny Warrants and potentially exercising them, leading to significant dilution at a very low price.
• The company's ability to raise capital through the equity line is discretionary and not an obligation of the investor, meaning the company may not be able to access the full $100,000,000 if market conditions are unfavorable or other conditions are not met.
• The company's ineligibility to use a Form S-3 registration statement for the existing Tranche B warrants required conversion to Form S-1, which can be a more burdensome and less flexible registration process.

Future Outlook

The company has secured a flexible equity line of credit to potentially raise up to $100 million, subject to market conditions and certain limitations. The restructuring of Tranche B warrants and the repurchase of Oramed's Penny Warrants aim to manage the capital structure and reduce potential dilution from very low-priced warrants, while also extending the maturity of a key promissory note. Future actions include filing registration statements for the new securities and potentially seeking stockholder approval for certain share issuances.

Industry Context

This filing reflects a common strategy in the biotechnology and pharmaceutical sectors, where companies often utilize equity lines of credit and manage their warrant liabilities to secure funding for ongoing operations, research and development, or strategic initiatives. The repurchase of low-exercise price warrants is a proactive measure to mitigate significant future dilution, a common concern for investors in growth-stage companies. The extension of debt maturity also indicates a focus on optimizing the company's financial runway.

Corporate Governance

Related Party Transactions

• The Option Agreement for the Repurchase of Warrants is with Oramed Pharmaceuticals Inc., which is also a holder of the company's Senior Secured Promissory Notes (Tranche A and Tranche B Notes), indicating a related party transaction.

Stakeholder Impact

• Shareholders: Will experience dilution from the equity line of credit and the increased number of shares underlying the new Tranche B warrants. However, the repurchase of low-exercise price Penny Warrants from Oramed could be seen as a positive for long-term shareholder value by reducing potential future dilution at a very low price.
• Creditors (Oramed): Benefits from the cash payments for the warrant repurchase and the extension of the Tranche A Note maturity date, improving the terms of their existing debt.

Next Steps

• File a Current Report on Form 8-K describing the terms of the transactions.
• File a Form D with respect to the issuance and sale of securities under Regulation D.
• File an Initial Registration Statement with the SEC to register the resale of shares issued under the equity line, including commitment shares.
• Potentially file a new registration statement to register the issuance of New Tranche B Warrant shares for cash exercise.
• Make the first option payment of $750,000 to Oramed by August 8, 2025.
• Pay remaining legal fees to Proskauer Rose LLP by September 15, 2025.
• Complete the first tranche of Oramed warrant repurchase (3,130,000 warrants for $13,000,000) by September 30, 2025.
• Make the second option payment of $750,000 to Oramed by December 16, 2025.
• Complete the second tranche of Oramed warrant repurchase (3,370,000 warrants for $14,000,000) by December 31, 2025.
• If required, seek stockholder approval for issuing shares exceeding the Exchange Cap or for Oramed's retained warrants.

Key Dates

Recommendation

The filing details significant capital structure adjustments. The new equity line provides a potential source of funding, which is crucial for growth-oriented companies. The repurchase of the deeply in-the-money Penny Warrants, while costly, removes a substantial overhang of cheap dilution. However, the increase in the number of shares underlying the new Tranche B warrants and the general dilutive nature of the equity line warrant a cautious 'hold' recommendation. Investors should monitor the company's utilization of the equity line, the impact of dilution on per-share metrics, and the strategic use of the capital raised.

Keywords

Equity Line of Credit, Warrant Exchange, Warrant Repurchase, Capital Raise, Dilution, SEC Filing, Common Stock, Corporate Finance, Debt Restructuring, Nasdaq Listing Rules